The conference

Our 2017 agenda will be our biggest ever.

With 4 tracks covering Therapeutic Innovation & Partnering, Biologics Manufacturing, Biosimilars & Vaccines,
this is your one-stop shop for mapping out your place in India’s biopharma future.

 

Create your personal agenda –check the favourite icon

09:00
Conference pass

Pharma Vision 2020, How close are we to the goal?

Keynotes
The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacturing. The Indian pharma market is expected to grow to US$ 55 billion by 2020. With the government implementing many new initiatives in its stride toward Pharma Vision 2020, how close are we to achieving it?
Suja Chandy, Vice President, Invest india
09:30
Conference pass

Boardroom panel: Creating a robust ecosystem for pharma in India

Keynotes
India is poised to become a top 5 global pharmaceutical hub by 2020. But in order to achieve this, there’s work to be done, to develop a successful ecosystem. Key stakeholders including the government, pharma, regulators and investors need to work closely together to build it. In this panel, we gather them to explore how, as we explore issues including:
 
  • How will the creation of new pharma clusters across India help enhance the ecosystem?
  • How is the Indian government playing an active role to help build up the ecosystem? (Building infrastructure, funding of incubators and accelerators, mission mode programmes)
  • Should a robust and sustainable ecosystem be centred around academic institutes to increase collaboration?
  • What are some existing models which India can emulate? (Boston,SF Bay area, Singapore, BioValley)
  • Is achieving that too idealistic? How far is India from achieving that?
11:30
Conference pass

LatAm: Investment, market access, and reimbursement issues in this key regional growth market

Keynotes
  • Highlighting the potential within the LatAm pharmaceutical markets
  • Regulatory reforms and deregulation in Mexico
  • Updates on the practical implementation of Mexico as a regional reference agency for other LatAm countries
  • Advantages for the registration of biologic drugs in LatAm
  • What it takes to successfully launch biologics in LatAm and their various reimbursement infrastructure
11:50
Conference pass

Meeting of 2 Pharma Giants in Asia: Opportunities and Challenges in China

Keynotes
  •     Updates on China’s market overview and opportunities
  •     Understanding regulatory challenges of entering China
  •     Exploring potential models for access (Partnerships, Acquisition or Direct Entry)
  •     Examining case studies of past failures and successes
Li Shi, Chief Executive Officer, Shanghai Zerun Biotechnology Co Ltd
12:10
Conference pass

Opportunities in the Middle East: Strategies to break into MENA region

Keynotes
  • Updates on reference pricing and GCC price unification for MENA region
  • Understanding the different financing models within MENA (Public financing of GCC vs Mixed financing of Near East and North Africa regions)
  • Strategies to overcoming slow and arduous regulatory processes in MENA
  • Growing interest of MENA countries in adopting HTA and pharma-economics for payer decision making
14:00
Conference pass

How is the biosimilars market developing globally and what does the future hold for biosimilars?

Biosimilars
As the drive for cheaper medicines continues, many companies are developing biosimilars as a cheaper alternative to novel biologics.
This panel discuss will look at the current global market conditions and explore future biosimilars trends.
  • Which biosimilars have recently been approved for sale in major markets and how did they do it?
  • Exploring the latest developments in biosimilars: What does it take to achieve scale?
  • What lies ahead for biosimilars in terms of regulations and IP?
  • How can India better establish itself in the global market?
Rebu Ninan, Director of Commercial Operations and Head of Global Marketing for Biologics, Dr. Reddy's Laboratories Limited
14:00
Conference pass

Global Vaccines Action Plan (GVAP): What is India’s role in this?

World Vaccines Congress India
  • Updates for GVAP Review Process & Indicators
  • How does it affect the industry?
  • With India already being the leading manufacturers in vaccines for the world, how better can we contribute?
14:00
Conference pass

Using automation to reduce human error in India’s biologics manufacturing

Biologics Manufacturing
  • Identifying prevalent human errors in manufacturing processes
  • Exploring possible automation solutions to eradicate
  • Analysis on productivity improvements
  • How does increased automation change the role of humans?
14:20
Conference pass

Sustainability of Vaccines Industry: Coping with pricing pressures

World Vaccines Congress India
India is supplying more than 60% of the vaccines procured by GAVI. Vaccines in the public market are older and mass manufactured. Due to the cost of production, new vaccines are not able to enter the market. Should local vaccine manufacturers focus on ensuring cheap production of old vaccines for the public market or should they develop new vaccines for their private market instead? This session will explore differences between public & private markets, together with strategies for navigating the public market.
  • Comparing the differences between public and private market in terms of development and production cost
  • Understanding the differences in demands for both markets
  • What are some challenges that are unique to the public market? (E.g. Price pressures from GAVI, WHO)
  • Explore strategies in overcoming these challenges to achieve a sustainable model
14:20
Conference pass

Preparing the workforce for shift towards biologics manufacturing in India

Biologics Manufacturing
    style="font-size: 10.0pt;">
  •     Understanding the skill and knowledge gaps in India’s current workforce
  •     Exploring strategies for improvement of capability of India’s workforce
  •     Case Study: Existing systems for continued training and education
14:40
Conference pass

Global scientific alignment of biogenerics drug development

Biosimilars
  • Scientific alignment versus harmonization – relevancy & complexities?
  • Emphasis on need for comprehensive data studies to demonstrate similarity
  • Addressing global regulatory key challenges in clinical development
Akhilesh Sharma, Senior Vice President and Global Head of Global Medical Affairs, Dr.reddy's Pharmaceutical Company
14:40
Conference pass

Highly accelerated platforms for mAb and next generation mAb development

Biologics Manufacturing
  •     Key elements of a mAb platform enabling gene to GMP in 9 months
  •     High throughput process development tools for developing next generation mAbs
  •     Challenges encountered with these novel types of molecules
  •     Rapid and streamlined process characterization and validation studies to enable BLA/MAA filings for breakthrough therapies and biosimilars 
15:00
Conference pass

How can regulators and pharma work closer together to establish a robust regulation framework?

Biosimilars
    style="font-size: 10.0pt;">Following India’s efforts to strengthen its regulatory landscape, there have been several updates and revisions of requirements and regulations. This constant changing in regulations has posed many challenges to pharma companies. This panel discussion explores how pharma and regulators can collaborate to establish a robust yet understandable regulatory framework. 
  •     What are some of the recent updates in regulations?
  •     How effective are the subject expert committee, therapeutic committee and apex committee in actioning change in policies?
  •     How can regulators and pharma work more closely together?
Sonika Shah, Head Regulatory Affairs, Amgen India
Anil Kukreja, Medical Director, Roche
15:00
Conference pass

Continuous processing: How does it impact drug quality

Biologics Manufacturing
  •     Exploring ways to better spot and correct errors by eliminating breaks between process steps
  •     Improving quality through better monitoring of process parameters (PAT)
  •     How built in tracking can ensure quality
15:20
Conference pass

Case Study: Novel platform technology for producing vaccines

World Vaccines Congress India
CPL’s recombinant nanoparticle platform technology
Nirav Desai, Vice President, CPL Biologicals
15:20
Conference pass

Determining optimum conditions for scaling down models in downstream processing

Biologics Manufacturing
  •     Making sure scaled down hardware is able to control and calibrate perimeters precisely and accurately
  •     Ensuring operational equivalence with all operational perimeters run at center of optimum range using large scale
  •     Understanding the importance of model qualification to pre determine acceptance criteria for scale down
15:40
Conference pass

Understanding post-market data and ADR reporting for biosimilars in India

Biosimilars
    style="font-size: 10.0pt;">
  •     Emphasising the importance of identifying immunogenicity for biosimilars
  •     Understanding impact of delayed ADR in biosimilars
  •     Utilizing Benefits-risk analysis to ensure safety
15:40
Conference pass

Case Study: Novel vectors and cell-line for producing vaccines

World Vaccines Congress India
Sementis’ SCV vector and CHO Rescue cell-line technology
Jane Ryan, CEO, Sementis
15:40
Conference pass

Determining optimum conditions for scaling down models in downstream processing

Biologics Manufacturing
  •     Making sure scaled down hardware is able to control and calibrate perimeters precisely and accurately
  •     Ensuring operational equivalence with all operational perimeters run at center of optimum range using large scale
  •     Understanding the importance of model qualification to pre determine acceptance criteria for scale down
16:30
Conference pass

Overcome the challenges of bringing biosimilars to market

Biosimilars
As the pharma market in India shifts from generics to biosimilars production, more and more players are entering the biosimilars market and competition is becoming stiff. In order to overcome the competition, Pharma has to ensure that they produce the products cheaper and faster. How can they do that?
  • How can Pharma reduce the cost of production?
  • What are some cutting edge technologies presently available to help manage the cost?
  • Are there capital and infrastructure investments that can be made to save cost in the long run?
Amardeep Udeshi, Head - Commercial Strategy, Cipla
16:30
Conference pass

Exploring JAPAC’s biosimilars market

Biosimilars
  • Market impact of Australia's current controversy in empowering pharmacies to substitute an original for Inflectra without prescriber consultation
  • What does Japan's 30% biosimilar price reduction mean to the manufacturer? Is this a discount to the Japanese borne by the government? How will this increased biosimilar market share in Japan impact Japan's biosimilar market?
  • With Celltrion and Samsung Bioepis in South Korea, does the country have room for international biosimilar investment?
16:30
Conference pass

Extractables and leachables testing using a Quality Risk Management approach

Biologics Manufacturing
  •     Understanding extractables and leachables for better adoption of single use systems
  •     Ensuring safety of drug through determining the level of leachables throughout product life cycle
  •     Case Study of implementation of standardized testing protocol​
Dhaval Tapiawala, Principal Scientist, Pfizer
16:30
Conference pass

Case Study: Synthetic Conjugate Vaccines

World Vaccines Congress India
MSD Wellcome Trust Hilleman Labs
16:50
Conference pass

Southeast Asia’s biosimilars market: Where do we go from here?

Biosimilars
Southeast Asia’s biosimilars market: Where do we go from here?
  • Understanding the ASEAN biosimilar regulation, the ACTR, ACTD and the ACCSQ
  • Leveraging Malaysia's growing biosimilars market and the demand for quality health in the country
  • Strategies around challenges in tech know-how and regulatory agencies different approaches and understanding of concepts
  • Crystal ball: What’s next on the horizon?
16:50
Conference pass

Case Study: New vaccines drug delivery methods

World Vaccines Congress India
Prokarium’s oral, thermostable Vaxonella platform to deliver a combination typhoid-paratyphoid vaccine
Ted Fjallman, CEO, Prokarium Ltd
16:50
Conference pass

Ensuring quality and stability in cell-line development

Biologics Manufacturing
  • Avoiding animal-origin material contact through use of a serum free medium
  • Exploring ways to address the translation, secretion and cell trafficking issues
  • Evaluating glycosylation and charge heterogeneity for consistency
Kaumil Bhavsar, Senior Scientist of Cell Culture, Intas Pharmaceuticals Ltd
17:10
Conference pass

Biosimilars IP wars Overview 2016: Lessons to learn

Biosimilars
  • Understanding the requirements and restrictions in obtaining IP protection for biosimilars
  • Comparing the different IP regulations in different countries
  • Case study: Roche’s Erlotinib/ Avastin/ Herceptin/ Pfizer’s Prevenar
Rahul Vartak, Director- Patents, Roche Pharmaceuticals
17:10
Conference pass

Case Study: Thermal Stability in Vaccines

World Vaccines Congress India
Serum Institute of India’s Phase III Rota Virus Vaccines
17:10
Conference pass

Utilizing Alternating Tangential Flow (ATF) for perfusion cell culture

Biologics Manufacturing
  • Comparing the difference between ATF and TFF in filtration
  • Cost-benefit analysis of ATF and TFF
  • Case Study

Create your personal agenda –check the favourite icon

09:10
Conference pass

Is the future of medicine personalised?

Keynotes
With the recent advancements in the study of genomics, much progress has been made creating medicines tailored specifically to an individual’s conditions and symptoms. Are we entering a new era of medicine with personalized medicine? To what extent are payers, providers, systems, physicians and patients ready for the change? How will digital technologies and solutions play into the vision of personalised medicine? What are the remaining challenges in making the vision of personalised medicine a reality?
09:35
Conference pass

An organised approach to promoting nation-wide innovation

Keynotes
When it comes to encouraging innovation centers in India, the government has a more decentralised approach where states have the flexibility and funds to build individual programs and innovation centers to promote the growth of biotech hubs. However, sometimes too many cooks may end up spoiling the broth. So how do different government units truly measure the real return of investment of these expenditures, and how do stakeholders work together in organising a more united approach to instilling real innovation within India?
 
10:00
Conference pass

Creating the workforce of the future: A case study on Biocon Academy

Keynotes
Biotechnology is a relatively young field in India, and it can sometimes be challenging to source for helpful manpower as real talented young individuals often get allured by overseas opportunities. This case study will share Biocon’s success story in building an academy with financial support and assistance to help young graduates to explore more options in their career, whilst growing essential talents to support the local ecosystem in India.
 
11:20
Conference pass

Are neoantigen vaccines the future of cancer vaccines?

World Vaccines Congress India
  •     What are some of the advances in personalized vaccines based on neoantigen?
  •     Exploring collaborations between institutions and pharma to further neoantigen research
  •     Case Study on Dana – Farber Cancer Institute and data presentation 
11:20
Conference pass

Process chromatography selection for downstream processing

Biologics Manufacturing
  • What are some of the new chromatography options available and how do they stack against existing ones?
  • Understanding key considerations such as biologics stability, buffer compatibility and ease of scale up
11:30
Conference pass

Biotech showcase

Biotech Innovation
Caroline Mathen, CEO, Co-Founder, OCT Therapies
11:40
Conference pass

Using therapeutic vaccines to cure HIV

World Vaccines Congress India
  •     Overview of progress in development of HIV vaccines
  •     Preliminary data presentation and case study 
11:40
Conference pass

Exploring the implementation of single use in downstream processing

Biologics Manufacturing
    style="font-size: 10.0pt;">
  •     Identifying the benefits of single use in downstream processing: Cost savings, reduced turnaround time, lower capital outlay & more
  •     Understanding the limitations of utilizing single use in downstream processing: Increased inventory, insufficient data on leachables & extractables, scalability
  •     Case Study of fully single use downstream processing
11:50
Conference pass

Biotech showcase

Biotech Innovation
12:00
Conference pass

Strategies for overcoming the downstream bottleneck for Cell and Gene Therapy (CGT)

Biologics Manufacturing
  •     Identifying the key areas of bottleneck in downstream processing (harvesting, washing, cell concentration, formulation, final fill/finish, and preservation)
  •     Balancing between high specificity and high throughput of downstream platforms for maximum efficiency
  •     Exploring ultra scale-down tools to better predict large scale downstream processing steps 
12:00
Conference pass

Biotech showcase

Biotech Innovation
Nusrat Jahan M. Sanghamitra, CEO and Founder, CyCa OncoSolutions
12:10
Conference pass

Biotech showcase

Biotech Innovation
Parul Ganju, Co- Founder, Executive Director, Ahammune Biosciences
14:10
Conference pass

Ensuring uniformity of GMP inspections in biologics manufacturing

Biologics Manufacturing
Countries across the globe are concerned about the safety and efficacy of the drugs supplied. As India expands its biologics supply globally, there is an increased emphasis in ensuring uniformity in inspection requirements for drugs manufactured in India. This panel discusses how global regulators such as US FDA, EMA can work closer together with CDSCO in ensuring uniformity in GMP inspections.
  • Overview of India’s inspection landscape and updates
  • Understanding the differences and overlaps in current standards
  • Exploring ways for various regulators to work closer together, including more combined inspections for newly recruited CDSCO inspectors
Mayur Parmar, Senior Drug Inspector, Gujarat FDA
K Bangarurajan, Deputy Drugs Controller West Zone, CDSCO
14:10
Conference pass

Single-window clearance for vaccines approval in India

World Vaccines Congress India
  • Updates of discussions with regulators for single-window clearance
  • How can companies work better together with regulators to streamline process?
14:20
Conference pass

Biotech showcase

Biotech Innovation
Rohan Kamat, C.E.O., Viravecs Labs
14:30
Conference pass

Understanding requirements of local trials data for approval

World Vaccines Congress India
    style="font-size: 10.0pt;">
  •     Case study: Sanofi’s Dengvaxia
  •     Understanding the rationale for the rejection of waiver of phase III trials of Dengue vaccines in Indian population
  •     Exploring the key considerations in using of global data to justify waiving of phase III studies in India
14:30
Conference pass

Biotech showcase

Biotech Innovation
Pradip Sinha, Co-Founder, InvivoD Solutions
14:50
Conference pass

Design and implementation of clinical trials in an emerging epidemic: Zika Trials in India

World Vaccines Congress India
  •     Clinical development challenges associated with the design and conduct of emerging epidemic trials
  •     Current status of Zika Vaccine candidates in Clinical Development
  •     Considerations for Zika Vaccine Clinical Development Strategy
  •     Case Study: Bharat Biotech 
14:50
Conference pass

Resolving the regulatory compliance issues in India

Biologics Manufacturing
  • Exploring solutions for data integrity issues in manufacturing plants
  • Ensuring proper recording of data for improved data quality
  • Emphasis on long term quality culture as compared to quick fix solutions.
Rajiv Dua, Site ATS Head – Corporate Quality and Compliance, SUN Pharmaceuticals
14:50
Conference pass
15:00
Conference pass
15:10
Conference pass

Lower price for more Access: How do we determine the sweet spot?

World Vaccines Congress India
  • Understanding the demand and potential of the private market in India
  • Explore strategies in maximizing profitability through pricing vs volume analysis
  • Case study: GSK
15:10
Conference pass

Best Practices for Analytical Method transfer: Lifecycle management perspective

Biologics Manufacturing
  • Emphasis on adequate method transfer as part of life cycle management
  • Understanding regulatory requirements for transfer
  • Continuous performance monitoring and management of analytical procedures following transfer
15:20
Conference pass

Biotech showcase

Biotech Innovation
Ravindra Patel, CEO, OmniBRx Biotechnologies Pvt ltd.
15:30
Conference pass

Understanding requirements of local trials data for approval

World Vaccines Congress India
  • Case study: Sanofi’s Dengvaxia
  • Understanding the rationale for the rejection of waiver of phase III trials of Dengue vaccines in Indian population
  • Exploring the key considerations in using of global data to justify waiving of phase III studies in India
15:30
Conference pass

Practical considerations for establishing analytical similiarity in biosimilars

Biologics Manufacturing
  • Assessment of critical quality attributes (CQA) and evaluation of tiers
  • Using risk management principles to supplement statistical approaches for assessment of analytical similarity for CQAs
  • Ranking of quality attributes based on potential impact on activity, PK/PD and immunogenicity
15:50
Conference pass

PCV Vaccine competition in India: Is $5 per dose possible?

World Vaccines Congress India
    style="font-size: 10.0pt;">
  •     Identifying current players in PCV vaccine manufacturing
  •     Exploring pricing strategies for PCV vaccine in India
  •     Ensuring stability and quality of vaccine
15:50
Conference pass

Development of liquid chromatography-Mass spectrometry (LC-MS/MS) based methods for pharmacokinetic and toxicokinetics study of biologics

Biologics Manufacturing
  • Advantages of LC-MS/MS based methods over ELISA methods
  • Parameters to be considered while developing LC-MS based methods for pK/tK  study
  • Challenges during method development and validation: requirement of stable isotope labeled internal standards
Dipak Thakur, General Manager, Genomics and Biotechnology, Wockhardt Ltd

 

GET THE SPONSORSHIP BROCHURE

 

Get involved

If you’d like to become an exhibitor, sponsor or speaker at the event
contact Pinky Fadullon at pinky.fadullon@terrapinn.com or +65 6322 2738